LeddarTech® Holdings Inc. ("LeddarTech") , an automotive software company that provides patented disruptive AI-based low-level sensor fusion and perception software technology, LeddarVisiontm, today ...

EQS-Adhoc: Merck KGaA: Merck KGaA confirms discussions with Springworks Therapeutics, Inc. on potential acquisition ...

In a report released yesterday, Umer Raffat from Evercore ISI maintained a Buy rating on Merck & Company (MRK – Research Report). The company’s shares closed yesterday at $89.67. Leverage the ...

As SpringWorks Therapeutics nears a key regulatory decision in the U.S., the Connecticut-based cancer and rare disease ...

Germany’s Merck KGaA is in advanced talks to aquire the U.S. biopharmaceutical company that specializes in rare diseases and cancer.

KGaA (MRK:GR) (OTC: MKGAF) stock from Overweight to Equalweight and reduced its price target from EUR190.00 to EUR160.00. The downgrade reflects a shift in the investment firm's perspective on the ...

Wall Street rebounds as tech stocks surge, with the S&P 500 up 0.5% amid easing trade tensions and strong corporate earnings.

Presents Analysis of Industry Giants, Including Thermo Fisher Scientific, Merck, Danaher Corporation, Sartorius, and Aceto ...

Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the fourth quarter and fiscal year of 2024, provided an update on progress toward achieving key ...

A key finding in January was the marked increase in procurement activity across North America. This increase was entirely ...

Significant growth trajectory of the Breast Cancer Application segment, which is expected to reach US$374.1 Million by 2030 ...

During an R&D update yesterday Merck said it is hoping to claim eight new cardiovascular therapy approvals between now and 2030, for diseases like atherosclerosis, heart failure, pulmonary ...